Figure S7 from Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase–Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type
Year: 2023
Type: other
Abstract: Mouse models of SCCOHT cell lines. A, Representative histology of kidney and liver from COV434-implanted mouse in the control group, and in the 30mg/kg ADI-PEG20 group which exhibited abnormal organs upon macroscopic examination at necropsy. B, BRG1 IHC for the masses above the heart found in 2 mice in the treatment groups. Top image: mass only (mouse DGH12-2-14); bottom image, mass adjacent to normal heart (mouse DGH12-2-15). C, tumor volume and weight of SCCOHT1 mouse model. Significance was calculated using ANOVA, followed by a post-hoc Tukey's test. Error bars represent standard error of mean. D, ASS1 re-expression in SCCOHT1 cells in both saline control group and 30mg/kg treated groups. E, Representative tunnel assay images from each treatment group indicating no significant increase in apoptosis in tumors from the ADI-PEG20 treated compared to saline-treated groups, and F, COV434 subcutaneous xenograft showing foci of ASS1 re-expression in treated groups. G, average mouse weight of each mouse model, and H, plots reflecting the tumour weight adjusted by mouse weight (tumour weight/mouse weight).
Authors: Jennifer X. Ji, Dawn R. Cochrane, Basile Tessier-Cloutier, Shary Yutin Chen, Germain Ho, Khyatiben V. Pathak, Isabel N. Alcazar, David Farnell, Samuel Leung, Angela Cheng, Christine Chow, Shane Colborne, Gian Luca Negri, Friedrich Kommoss, Anthony Karnezis, Gregg B. Morin, Jessica N. McAlpine, C. Blake Gilks, Bernard E. Weissman, Jeffrey M. Trent, Lynn Hoang, Patrick Pirrotte, Yemin Wang, David G. Huntsman
Language: English
Subfield: Biotechnology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361889134